Evaluation of the LMWH Thromboprophylaxis in Pregnancy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01394107|
Recruitment Status : Unknown
Verified July 2015 by Jan Blaha, MD, PhD., Charles University, Czech Republic.
Recruitment status was: Recruiting
First Posted : July 14, 2011
Last Update Posted : July 29, 2015
|Condition or disease|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Observational Model:||Case Control|
|Official Title:||Evaluation of the Impact of the Thromboprophylactic Dose of LMWH on Coagulation in Pregnant Women.|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||December 2015|
50 pregnant women with physiological ongoing pregnancy and undergoing planned caesarean section, without known coagulation disorders, will be included in to the study.
Inclusion criteria: pregnant women undergoing planned caesarean section, 39th-40th week of pregnancy, age 18-40 years, informed consent.
50 healthy women in fertility age (18-40 years) undergoing elective surgery for other than oncology or inflammatory indication, without known risk factors for coagulation disorders, not using hormonal contraception, informed consent.
- Effect of standard prophylactic dose of LMWH on coagulation in pregnant women [ Time Frame: 24 hours after LMWH application ]To map the coagulation effect of standard prophylactic dose of LMWH in pregnant women at the end of pregnancy. Based on these results, to evaluate the possible prophylactic effect of LMWH on TED prevention in pregnant compared to non-pregnant women.
- Evaluation of the possible influence of LMWH on the potential risk of spinal hematoma development during neuraxial blockade in pregnancy. [ Time Frame: 24 hours after LMWH application ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01394107
|Contact: Jan Blaha, md, PhD||+420 email@example.com|
|General University Hospital in Prague||Recruiting|
|Prague 2, Czech Republic, 128 08|
|Contact: Jan Blaha, MD, PhD +420 224947241|
|Principal Investigator: Jan Blaha, MD, PhD|
|Principal Investigator:||Jan Blaha, MD, PhD||Charles University, 1st Medical Faculty in Prague|